Swiss healthtech startup Moonlight AI has secured €2.8 million ($3.3 million) in Seed funding to accelerate the development of its AI-based diagnostic platform for haematology and oncology applications.
The round was co-led by Lotus One Investment, VP Venture Partners, and MEDIN Fund, with additional backing from N&V Capital and existing investor QAI Ventures.
Bringing AI Into Clinical Diagnostics
Founded in 2022, Moonlight AI develops image analysis software designed to help laboratories extract genomic insights directly from standard medical images.
Its platform uses computer vision and AI to identify genomic biomarkers and disease signatures, enabling clinicians to deliver faster and more precise cancer diagnoses while supporting personalised treatment decisions.
The company is focused on addressing limitations associated with traditional Next-Generation Sequencing (NGS), which can often be expensive, resource-intensive, and slow.
By integrating with existing laboratory imaging systems, Moonlight AI aims to streamline workflows, shorten diagnostic turnaround times, and improve efficiency within clinical environments.
Advertisement
Expanding Diagnostic Capabilities
The newly raised capital will be used to expand the company’s proprietary medical imaging and biomarker dataset, while advancing diagnostic solutions for diseases including myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukaemia (CLL).
The company also plans to accelerate regulatory approvals and commercial rollout efforts as it expands internationally.
As part of its growth strategy, the company has transitioned into a Swiss Stock Corporation (Aktiengesellschaft) to support future scaling and global operations.
Christian Ruiz, CEO and co-founder of Moonlight AI, said the company’s technology enables laboratories to generate actionable diagnostic insights using existing slide-based workflows without requiring expensive new hardware or highly manual processes.
About Moonlight AI
Moonlight AI is a Swiss AI diagnostics startup developing computer vision software for cancer detection and precision medicine. Its platform transforms routine medical images into clinically relevant genomic insights, helping healthcare providers improve diagnostic speed, accuracy, and treatment selection across oncology applications.
